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Summary. Background and Objective. In external preparations, types and ratios of additives 
are not necessarily the same for brand-name drugs and generic drugs. Thus, the physicochemical 
properties of preparations may differ despite the fact that they contain the same ingredients or addi-
tives. This study examined differences in brand-name and generic versions of nadifloxacin (NFX) 
creams.
Material and Methods. Three types of NFX creams (NFX-A, NFX-B, and NFX-C) were used. 
The viscosity of each preparation was determined, its yield value was calculated, and each prepa-
ration was subjected to light microscopy, x-ray powder diffraction, and near-infrared absorption 
spectroscopy.
Results. Comparison of viscosity of different preparations revealed that NFX-B had a lower 
viscosity than NFX-A and NFX-C (14.5 vs. 24.6 and 17.9 Pa·s). NFX-B also had a lower yield 
value than NFX-A and NFX-C. Microscopy revealed that NFX-A and NFX-B had satisfactory 
emulsification although crystallization was observed with NFX-C. Near-infrared absorption spec-
troscopy revealed changes in the absorption spectra of NFX-B in comparison with those of NFX-A 
and NFX-C that were due to differences in water content and differences in fat and oil content.
Conclusions. These findings confirmed that there were differences in the viscosity and flattening 
of NFX-A, NFX-B, and NFX-C. In addition, microscopy revealed differences in emulsification 
and it revealed the precipitation of NFX crystals in NFX-C. Near-infrared absorption spectroscopy 
revealed that differences in the type and amount of additives and water content in the creams had 
contributed to differences in the preparations. 
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Introduction
The rationalization of health care expenditures 
is a high priority for the governments of many 
countries in the industrialized world. Generic drugs 
contain the same active ingredients as their brand-
name counterparts, but they have different addi-
tives such as preservatives and coloring agents (1). 
Generic formulations are made by the same manu-
facturer as the brand-name drug, but their quality 
is often questioned by physicians and pharmacists 
since the excipients used may differ. Generics regis-
tered with the European Medicines Agency (EMA) 
should include the same amount of the active ingre-
dients but can have different excipients. Excipients 
that are given exceptions include preservatives, pH 
adjusters, antioxidants, thickening agents, buffers, 
and substances to adjust tonicity. Although generic 
formulations are always less expensive than the cor-
responding brand-name drugs, they are not always 
as safe or effective. In addition, generic drugs are 
considered to be of the same quality as the original 
drugs, but many feel that information about those 
generics is inadequate (2). Among physicians, there 
are perceptions that generic drugs will immediately 
be discontinued and concerns about consistent sup-
ply. Such factors might explain why generic drugs 
have gained little attraction in Japan despite ac-
counting for half of the drug market in the United 
States and the United Kingdom (3, 4). As stated 
earlier, although generic formulations are always 
less expensive than the corresponding brand-name 
drugs, they are not always as safe or effective. When 
a generic drug is registered with the EMA, the clini-
cal efﬁ cacy and safety of that generic is considered 
essentially similar to the innovator or brand-name 
drug, and the same holds true for local-acting drugs. 
That said, topical agents in the form of ointments 
and creams are used to treat a local inﬂ ammation 
or rash, so reports have indicated that differences 
in additives and differences in additive content can 
lead to differences in penetration of and absorption 
by the skin, in turn affecting the therapeutic effec-
tiveness of the ointment or cream (5–7). Penetra-
tion of the skin by the antiviral acyclovir (ACV) is 
reported to differ with preparations that contain dif-
ferent amounts of polyethylene glycol. All marketed 
ACV creams are not bioequivalent to the clinically 
proven innovator (8). Substantial differences in bio-
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availability are believed to bring into question the 
therapeutic equivalence of these formulations.
Nadiﬂ oxacin (NFX) is a tricyclic ﬂ uoroquino-
lone antibiotic with a benzoquinolizine skeleton and 
is the active ingredient in the world’s ﬁ rst quinolone 
topical preparation, Acuatim® (9). Since it contains 
ﬂ uorine (F), NFX is a synthetic bactericidal ﬂ uo-
roquinolone with a broad-spectrum antibacterial 
activity against aerobic gram-positive and gram-
negative bacteria and anaerobic bacteria including 
Propionibacterium acnes and Staphylococcus epidermi-
dis; NFX is also clinically useful in treating acne vul-
garis (10, 11). NFX has been found to have a broad 
antibacterial spectrum. Formulations are available in 
3 forms – creams, lotions, and ointments – for use in 
accordance with the patient’s condition. NFX creams 
that have recently come into use include both brand-
name and generic versions. However, differences in 
the types or amounts of additives in a cream that is 
used locally would presumably affect the physico-
chemical properties of preparation, such as its emul-
siﬁ cation and viscosity. To test this hypothesis, the 
physicochemical properties of a brand-name NFX 
cream were compared with those of two leading ge-
neric NFX creams. This study sought to observe the 
characteristics of preparations, determine their vis-
cosity, and assay those preparations as a quality test. 
In addition, this study examined the molecular state 
of those preparations resulting from differences in 
additives they contained.
Materials and Methods
Reagents. The NFX creams used were those 
available commercially and were designated NFX-
A (Acuatim®), NFX-B (NADIFLO®), and NFX-C 
(NADIROXISAN®). NFX crystals were purchased 
from Sigma-Aldrich. Acetonitrile, chloroform, so-
dium hydroxide, and acetic acid were of special 
commercial grade and were purchased from Wako 
Pure Chemical Industries.
Preparation of Humidity-Controlled Samples. 
NFX-A, NFX-B, and NFX-C were stored in a ther-
mostated bath at 40°C for 7 days in a desiccator 
(relative humidity, 82%) in the presence of KCl-
saturated aqueous solution.
Microscopy. Polarization microscopy was done 
using an OLYMPUS model BX51 microscope. In 
addition, a polarizing plate with a wavelength of 488 
nm was used.
Determination of Viscosity. Viscosity was meas-
ured at 20°C using a type-E rotational viscometer 
(model TVE-20H) from Toki Sangyo. One milliliter 
of each cream was poured into a sample cup, and 
viscosity was measured at 1 rpm using a 1°34´×R24 
cone rotor; measuring time was 900 s, and viscosity 
was read after 180 s of rotation. Creams were incu-
bated in a water bath at 20°C before measurements.
Measurement of Flattening. Flattening was meas-
ured using a spread meter (Rigo) with a measuring 
temperature of 25°C. Spread diameter was meas-
ured after 10, 30, 60, 120, 180, 240, 300, and 360 s. 
The yield value was calculated from the following 
formula using the spread diameter after 360 s:
F=47 040×G×V/π2×d5
Where F indicates yield value (dynes/cm3); G, 
glass plate weight (g); V, sample volume (cm3); d, 
diameter (mm) when sample spreading stopped.
Near-Infrared Absorption Spectroscopy. Near-
infrared absorption spectra were recorded from 
1000 to 2500 nm at 1-nm intervals using a Fourier-
transform near-infrared analyzer (BUCHI NIRFlex 
N-500).
X-Ray Powder Diffraction. X-ray powder dif-
fraction was measured at room temperature with a 
Rigaku Miniﬂ ex Diffractometer using CuKα radia-
tion. Diffraction was done at 30 kV, 15 mA with a 
scanning speed of 4°/min and measurement range 
of 2θ=5°–35°.
Assay. One gram of each cream was weighed 
accurately and placed in a stoppered centrifuge 
tube. Twenty milliliters of chloroform/0.01 mol/L 
sodium hydroxide (1:1) was added, and the solu-
tion was shaken and then centrifuged (4000 rpm for 
30 min). The clear portion of the top layer was ﬁ l-
tered with a 0.45-μm ﬁ lter, and the ﬁ ltrate served 
as the sample solution. A calibration curve was pre-
pared using NFX that had separately been dried for 
24 h at 105°C. NFX was assayed with a high-perfor-
mance liquid chromatograph (HPLC, LC-20ADvp, 
Shimadzu). NFX assay conditions were a column 
of Inertsil ODS-3 (4.6×250 mm, φ5 μm), column 
temperature of 35°C, mobile phase of water/aceto-
nitrile/acetic acid=130/70/1, and detection wave-
length of 280 nm; conditions were tailored for NFX 
to produce a peak at 15 min.
Results 
In the current study, viscosity was determined us-
ing a rotational viscometer so that individual creams 
could be compared (Fig. 1). NFX-A, NFX-B, and 
NFX-C had a viscosity of 24.6 Pa·s, 14.5 Pa·s, and 
17.9 Pa·s, respectively, so results in order of viscos-
ity were NFX-A>C>B. A spread meter was used to 
compare the ﬂ uidity of the creams, and the results 
of this comparison are shown in Fig. 1 and Table 1. 
After 360 s, NFX-B had a spread diameter of 41.5 
mm, NFX-C had a spread diameter of 39.9 mm, and 
NFX-A had a spread diameter of 35.3 mm. Flattening 
was greatest for NFX-B, followed by NFX-C and then 
NFX-A. As an indicator of hardness, the yield value 
was 498.4 dynes/cm2 for NFX-A, 222.9 dynes/cm2 
for NFX-B, and 270.6 dynes/cm2 for NFX-C. Thus, 
light microscopy was used to examine the emulsiﬁ -
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cation of the preparations. The results of polariza-
tion microscopy of NFX-A, NFX-B, NFX-C, and 
NFX crystals are shown in Fig. 2. Results revealed 
that NFX-A and NFX-B were evenly and uniformly 
dispersed in general. In contrast, NFX-C was found 
to have clefts and precipitation of needle-shaped 
crystals. These ﬁ ndings conﬁ rmed that NFX-A and 
NFX-B were uniformly emulsiﬁ ed, but crystals and 
voids were found in NFX-C, indicating that NFX-C 
was not uniformly emulsiﬁ ed. Since crystals were 
found in NFX-C, NFX-C was irradiated with light 
at a wavelength of 488 nm and observed. Its needle-
shaped crystals were found to ﬂ uoresce. When NFX 
crystals were irradiated with light at a wavelength of 
488 nm, they had similar ﬂ uorescence (Fig. 3).
X-ray powder diffraction patterns of NFX-A, 
NFX-B, NFX-C, and NFX crystals were obtained 
in order to study the crystals observed in polariza-
tion microscopy (Fig. 4). NFX crystals were found 
to have a characteristic peak at 2θ=20.3°. NFX-A, 
NFX-B, and NFX-C were found to have peaks at 
approximately 2θ=21.0°. However, an interesting 
ﬁ nding is that NFX-C was found to have an x-ray 
diffraction peak at 2θ=20.4°, unlike the peaks of 
NFX-A and NFX-B.
Near-infrared absorption spectroscopy was per-
Fig. 1. Viscosity curves for nadiﬂ oxacin (NFX) creams at 20°C
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Table 1. Spreadability of Nadiﬂ oxacin (NFX) Cream at 25°C 
(n=3)
Fig. 2. Light microscopy of nadiﬂ oxacin (NFX) crystals and creams 
A, NFX crystals; B, NFX-A; C, NFX-B; and D, NFX-C.
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formed to examine the molecular state of the 
creams (Fig. 5). Results revealed that the spectra of 
NFX-A, NFX-B, and NFX-C lacked the character-
istic peak of NFX crystals. Since the preparations 
had a low NFX content (1%), NFX peaks may have 
overlapped because of excipients in the prepara-
tions. With fatty bases, spectra resulting from oleﬁ n 
groups have been observed in the regions between 
4200 and 4400 cm–1 as well as 5600 and 5800 cm–1 
(12). As shown in Fig. 6, NFX-A and NFX-C had 
roughly the same content based on the second de-
rivative of the near-infrared absorption spectra, but 
NFX-B was found to have slightly fewer fats and 
oils than did the other 2 creams. Spectra presumably 
due to differences in water content resulting from 
hydroxyl groups have been observed in the region 
between 5100 and 5400 cm–1 (13). Based on differ-
ences in absorption spectra, water content was high-
est in NFX-B, followed by NFX-C and then NFX-
A; NFX-B in particular had a higher water content 
than the other 2 creams. Thus, the second derivative 
of near-infrared absorption spectra of excipients is 
shown in Fig. 7. Results indicated that spectra of 
individual excipients were similar regardless of the 
region; NFX-C was found to have a spectrum simi-
Fig. 3. Morphology of nadiﬂ oxacin (NFX) crystals and creams according to polarized light microscopy 
at a light wavelength of 488 nm
A, NFX crystals; B, NFX-A; C, NFX-B; and D, NFX-C.
A B
C D
100 μm 100 μm
100 μm100 μm
Fig. 4. Comparison of the x-ray powder diffraction patterns 
of nadiﬂ oxacin (NFX) crystals and NFX creams
A, NFX crystals; B, NFX-A; C, NFX-B; and D, NFX-C.
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lar to that of isopropyl myristate in the region be-
tween 5900 and 6100 cm–1. An assay using HPLC 
was performed to study the NFX content in creams, 
and the results of this assay are shown in Table 2. 
Results revealed that NFX-A, NFX-B, and NFX-C 
had an NFX content of 90% or more.
Discussion
Pharmaceutical creams have rheologic properties 
that are crucial to the physical performance of the 
product when used by the consumer. Most creams 
are intended to be thick when standing to prevent 
them from ﬂ owing away from the intended area of 
use. Differences in additives contained in prepara-
tions may affect the ﬂ attening and adherence of 
Fig. 5. Near-infrared spectra of nadiﬂ oxacin (NFX) 
crystals and NFX creams
A, NFX crystals; B, NFX-A, NFX-B, and NFX-C.
Fig. 6. Second derivative of near-infrared spectra 
of nadiﬂ oxacin (NFX) creams
A, 4000–4500 cm–1; B, 5000–5500 cm–1; 
and C, 5500–6000 cm–1.
Fig. 7. Second derivative of near-infrared spectra of excipients
A, 4400–4600 cm–1; B, 5800–6100 cm–1.
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creams. Results of comparing the viscosity and ﬂ at-
tening of NFX creams in this study indicated that 
individual preparations had different physicochemi-
cal properties. Because of viscosimetry, high viscos-
ity at a near zero shear rate characterizes this be-
havior; determining the yield stress value quantiﬁ es 
this desired property. Creams are also engineered to 
be easy to apply when rubbed. Differences in vis-
cosity as were noted here are thought to occur due 
to differences in the type and amount of additives 
contained in the preparations. In addition, NFX-C 
was more likely to have a slightly higher viscosity 
at about 500 s and 700 s. Typically, when a cream 
is uniformly emulsiﬁ ed, its viscosity is found to de-
crease with time. However, determining the viscos-
ity of NFX-C was hampered, so NFX-C is surmised 
to have a different level of emulsiﬁ cation than that 
found in NFX-A and NFX-B. From a result of the 
ﬂ atting measurement, NFX-C spread unevenly 
and not in a concentric fashion. If the preparation 
were adequately emulsiﬁ ed, viscosity and ﬂ attening 
would be measured consistently. However, determi-
nation of viscosity revealed that viscosity tempo-
rarily increased approximately 500 s and 700 s for 
NFX-C, and differences in ﬂ attening and the yield 
values of preparations were noted. Such ﬁ ndings 
may indicate that differences in additives affected 
the physical properties of the preparations. When 
NFX crystals were irradiated with light at a wave-
length of 488 nm, they had similar ﬂ uorescence, so 
the NFX-C crystals are surmised to be NFX crystals 
(Fig. 3). As shown in Fig. 4, the fact that similar 
powder x-ray diffraction peaks appeared for the 3 
preparations may be due to excipients contained in 
the preparations. The NFX-C was found to produce 
powder x-ray diffraction peaks at 2θ=20.4°. This 
peak coincides with the peak due to NFX crystals, so 
results suggested that the NFX-C crystals observed 
with polarization microscopy are NFX crystals. In 
terms of the typical changes in viscosity over time, 
if a certain amount of force is applied and a yield 
value of the substance is exceeded, then its structure 
will be disrupted. Its viscosity will decrease and the 
substance will ﬂ atten out. Under conditions where 
a substance structure is disrupted, its viscosity will 
seldom increase again. However, NFX-C was found 
to have a temporary increase in viscosity at 500 s 
and 700 s. This was potentially caused by the prepa-
ration not being uniformly dispersed since the NFX 
crystals in NFX-C precipitated. In light of these 
ﬁ ndings, NFX crystal precipitation and emulsiﬁ ca-
tion are surmised to have contributed to differences 
in the emulsiﬁ cation and viscosity of the creams. 
Based on these ﬁ ndings of the near-infrared absorp-
tion spectroscopy, the small amount of fats and oils 
and high water content in NFX-B may have been 
factors that affected the viscosity and ﬂ attening of 
the preparation. In other words, differences in the 
viscosity and ﬂ attening of the creams may reﬂ ect 
differences in the content and quality of fats and 
oils in additives and differences in water content. 
The spectrum for NFX-C was found to have its 
peak in a different location than the peaks of spec-
tra for NFX-A and NFX-B in the regions between 
4400 and 4500 cm–1 as well as 5800 and 6100 cm–1. 
This may indicate differences in spectra that arose 
because of differences in excipients in the prepara-
tions. As shown in Fig. 7, neither NFX-A nor NFX-
B contained isopropyl myristate as an excipient, so 
this additive is thought somehow to affect the emul-
siﬁ cation of the cream. The properties of individual 
creams differ, so presumably this would affect an 
assay of NFX and its stability. Precipitation of NFX 
crystals in NFX-C was conﬁ rmed by microscopy. 
Since an assay using HPLC was performed by dis-
solving creams in a solvent and quantitatively meas-
uring NFX, results were converted into the NFX 
content. Disparities in absorbance by and feel on 
the skin are thought to occur when creams are ac-
tually used clinically despite an assay indicating an 
NFX content of 90% or more. Clearly, differences 
among NFX-A, NFX-B, and NFX-C arose because 
of compounding ratios and manufacturing processes 
despite the preparations being formulated with the 
same additives. These differences are expected to af-
fect the emulsiﬁ cation of creams. Thus, differences 
in the emulsiﬁ cation technique used in the cream 
may affect the preparation, but differences in emul-
siﬁ cation, viscosity, and additives may be reﬂ ected 
in differences in how the preparation feels on the 
skin in clinical settings. In other words, differences 
in ﬂ attening lead to different amounts applied by 
patients in clinical settings and different feel on the 
skin, and these variations may affect the therapeu-
tic effectiveness of the preparation. Near-infrared 
absorption spectroscopy, a nondestructive method 
of analysis, is a useful method of identifying dif-
ferences in preparations (14). As the current study 
indicated, differences may affect skin penetration 
since preparations are used on areas with a thin layer 
of skin, like the face, to treat conditions like acne. 
In a study using corticosteroids, Stoughton reported 
that preparations with different additives resulted in 
different levels of bioavailability despite the prepa-
rations having the same active ingredients and the 
Cream 
Type
Nadiﬂ oxacin Content, mg/mL
No. 1 No. 2 No. 3 Total, mean (SD) 
NFX-A
NFX-B
NFX-C
0.969
0.899
1.038
0.969
0.946
1.011
0.971
0.949
1.021
0.970 (0.001)
0.931 (0.028)
1.023 (0.013)
Table 2. Mean Nadiﬂ oxacin (NFX) Content Measured 
by High-Performance Liquid Chromatography (n=3)
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same amount being applied (6). Near-infrared ab-
sorption spectroscopy revealed differences in water 
content and the type and amount of additives in the 
NFX preparations studied here. In addition, results 
suggested differences in emulsiﬁ cation, so these dif-
ferences may affect the coefﬁ cient of drug diffusion 
across the stratum corneum and lead to disparities in 
therapeutic effectiveness. The 3 NFX creams exam-
ined in this study were found to have different prop-
erties, despite having the same active ingredients, 
due to differences in the type and amount of ad-
ditives they contained. These differences may affect 
the feel on the skin and therapeutic effectiveness of 
the preparation when it is actually used by patients. 
Studying the physicochemical properties of prepara-
tions is a useful way to collect information on a drug. 
Elucidating differences in the properties of individu-
al preparations should provide useful information for 
the assessment and selection of preparations.
Conclusions
Differences in the viscosity and ﬂ attening of 
NFX-A, NFX-B, and NFX-C were noted. In ad-
dition, microscopy revealed differences in emul-
siﬁ cation and it revealed the precipitation of NFX 
crystals in NFX-C. Near-infrared absorption spec-
troscopy revealed that differences in the type and 
amount of additives and water content in the creams 
contributed to differences in the preparations.
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